Efficacy and tolerability of exclusive enteral nutrition in adult patients with complicated Crohn’s disease
- Author:
Sanchit SHARMA
1
;
Arti GUPTA
;
Saurabh KEDIA
;
Samagra AGARWAL
;
Namrata SINGH
;
Sandeep GOYAL
;
Saransh JAIN
;
Vipin GUPTA
;
Pabitra SAHU
;
Sudheer Kumar VUYYURU
;
Bhaskar KANTE
;
Raju SHARMA
;
Rajesh PANWAR
;
Peush SAHNI
;
Govind MAKHARIA
;
Vineet AHUJA
Author Information
- Publication Type:Original Article
- From:Intestinal Research 2021;19(3):291-300
- CountryRepublic of Korea
- Language:English
-
Abstract:
Background/Aims:Exclusive enteral nutrition (EEN), an established modality for pediatric Crohn’s disease (CD) is seldomly utilized in adults. The present study reports the outcome of EEN in adult CD patients at a tertiary care hospital in India.
Methods:This was a retrospective analysis of CD patients who received EEN as a sole modality/adjunct to other treatment. The primary and secondary outcomes changed in Crohn’s Disease Activity Index (CDAI), and clinical response (decline in CDAI > 70), respectively, at 4 and 8 weeks. Subgroup analysis evaluated response across different phenotypes, EEN formulations and prior treatment. Linear mixed effect model was created to assess the predictors of EEN response.
Results:Thirty-one CD patients received EEN over median duration of 4 weeks (range, 2–6 weeks). CDAI showed a significant improvement post EEN at 4 (baseline 290 [260–320] vs. 240 [180–280], P= 0.001) and 8 weeks (baseline 290 [260–320] vs. 186 [160–240], P= 0.001), respectively. The cumulative clinical response rates at 4 and 8 weeks were 37.3% and 80.4% respectively. The clinical response rates at 8 weeks across B1 (n = 4), B2 (n = 18) and B3 (n = 9) phenotypes were 50%, 78.8% and 100% respectively (log-rank test, P= 0.093). The response rates at 8 weeks with polymeric (n = 8) and semi-elemental diet (n = 23) were 75% and 82.6%% respectively (log-rank test, P= 0.49). Baseline CDAI (odds ratio, 1.008; 95% confidence interval, 1.002–1.017; P= 0.046) predicted response to EEN.
Conclusions:EEN was effective in inducing clinical response across different phenotypes of CD. Baseline disease activity remained the most important predictor of clinical response to EEN.
